AIStockmoo 评分
| 价值 30% | 0.0 |
| 负债低。盈利能力弱。短期流动性充足。现金流为负。 参考 | |
| 来自我们的 AI Insight 报告对预期回报与风险的评估。 参考 | NA |
| 相对估值 参考 | NA |
| 隐含增长 参考 | NA |
| 历史估值 参考 | NA |
| 资本回报 参考 | NA |
| 持仓估值 参考 | NA |
| 风险溢价 参考 | NA |
| 市场估值 参考 | NA |
| 时机 30% | -5.0 |
| 过去一年呈下降趋势。股价远低于52周高点。 参考 | |
| 下降趋势:股价位于均线之下,均线向下。股价接近均线。 参考 | |
| 来自我们对走势图的 AI 技术分析。 参考 | NA |
| K线形态 参考 | NA |
| 市场情绪 20% | 0.0 |
| 近期没有目标价,因此依据目标价的调整方向。 参考 | |
| 持仓情绪 参考 | NA |
| 新闻情绪 参考 | NA |
| 聪明钱 20% | -4.0 |
| 机构在最新13F申报中净-3.72%的股份:5家增持,11家减持(截至30 Sep 2026的季度)。 参考 | |
| 内部交易活动 参考 | NA |
| 市场和行业状况不佳。 | |
| 市场环境偏谨慎。 参考 | |
| 行业表现落后大市。 | |
| 各支柱方向一致,评分因此加强。 | |
| 不计入评分 | |
| 每股盈利大多下降。近年曾亏损。 参考 | |
| 低于中期趋势线。 参考 | |
| 股价低于其52周平均水平。5年来下跌。 参考 | |
| 短期动能下降。 参考 | |
| 股价接近支撑位。 参考 | |
| 最终评分 | -3.26 |
市场趋势
| 短期 | 中期 | ||
| 行业 | Biotechnology (US) | 混合的 | 看涨 |
| Biotechnology (全球的) | 混合的 | 看涨 | |
| 股票 | Kairos Pharma, Ltd. | - | - |
相关股票
| 股票 | 市值 | DY | P/E(TTM) | P/B | 评分 |
|---|---|---|---|---|---|
| KAPA | 2 M | - | - | 0.420 | -3.3 |
| CYBN | 359 M | - | - | - | 0.0 |
| NRXS | 60 M | - | - | 18.58 | -1.2 |
| CVM | 21 M | - | - | 2.22 | -3.7 |
| NHWK | 20 M | - | - | 0.260 | 0.0 |
| AEON | 10 M | - | - | - | -3.3 |
|
Kairos Pharma, Ltd. operates as a clinical-stage biopharmaceutical company that develops therapeutics for cancer patients. Its therapeutics include antibodies and small molecules for the treatment of prostate cancer, lung cancer, breast cancer, and glioblastoma. Kairos Pharma, Ltd. was formerly known as NanoGB13, Inc. and changed its name to Kairos Pharma, Ltd. in July 2016. The company was incorporated in 2013 and is based in Los Angeles, California. |
|
| 部门 | Healthcare |
| 行业 | Biotechnology |
| 内部持股比例 | 24.29% |
| 机构持股比例 | 3.45% |
所有权
| 姓名 | 日期 | 持有股份 |
|---|---|---|
| Aptus Capital Advisors, Llc | 30 Sep 2026 | 0 |
| Sevenbridge Financial Group, Llc | 30 Sep 2026 | 0 |
该时间范围内无数据。
机构
机构持股比例: 1.20%
| 持仓变动 | 机构数 | 股数 |
|---|---|---|
| 增持 | 5 | 14,551 |
| 减持 | 11 | 115,458 |
| 新建仓 | 2 | 4,680 |
| 清仓 | 9 | 89,782 |
来源:经Nasdaq的SEC 13F申报,最新申报截至30 Sep 2026。申报在每季结束后45天内陆续提交。
0 正面
0 负面
2 中性
| 日期 | 类型 | 细节 |
|---|---|---|
| 05 Nov 2026 | Yahoo Finance |
Kairos Pharma Recognized by Biotech Breakthrough Awards in Oncology
LOS ANGELES, November 05, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company targeting drug resistance in cancer, announces that it has been named a winner of the 2026 Biotech Breakthrough Awards in the category of Cancer Immunology Solution of the Year for… |
| 03 Nov 2026 | Yahoo Finance |
Kairos Pharma Presents at United Scientific Group’s 11th International Conference on Cancer Research & Drug Development
LOS ANGELES, November 03, 2026--Neil Bhowmick, President and CSO of Kairos Pharma, presents on lead candidate ENV-105 and its interim efficacy results at Cancer R&D 2026… |
| 22 Oct 2026 | Yahoo Finance |
CEO.CA's Inside the Boardroom: Major U.S. Cancer Centers Are Testing This New Drug: Kairos Pharma
Toronto, Ontario--(Newsfile Corp. - October 22, 2026) - CEO.CA ("CEO.CA"), the leading investor social network in venture stocks, shares exclusive updates with CEOs and executives from around the globe.Founded in 2012, CEO.CA, a wholly owned subsidiary of EarthLabs, Inc., is one of the most popular… |
| 06 Oct 2026 | Yahoo Finance |
Kairos Pharma Reports Positive, Statistically Significant Interim Efficacy Data from Phase 2 Trial of ENV-105 in Metastatic Prostate Cancer
LOS ANGELES, October 06, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company addressing drug resistance in cancer, today announced positive interim efficacy data from its ongoing Phase 2 clinical trial evaluating ENV-105 (carotuximab) in combination with… |
| 23 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present and Moderate at Discovery on Target Conference in Boston, MA
LOS ANGELES, September 23, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that Neil Bhowmick, President and Chief Scientific Officer, will both present and moderate a discussion in person at the… |
| 09 Sep 2026 | Yahoo Finance |
Kairos Pharma to Present at the H.C. Wainwright 28th Annual Global Investment Conference
LOS ANGELES, September 09, 2026--Kairos Pharma, Ltd. (NYSE American: KAPA), a clinical-stage biopharmaceutical company focused on overcoming cancer drug resistance, announces that John Yu, MD, CEO and Chairman, will present in person a corporate overview at the H.C. Wainwright 28th Annual Global… |
技术形态 中期
趋势排列
斜率
入场位置
成交量
下降趋势:股价位于均线之下,均线向下。股价接近均线。
最近支撑: 0.362 – 0.437 · 中等
最近阻力: 0.452 – 0.490 · 中等
AI 技术分析
投资组合